In this week's video, Dr. Brian G.M. Durie discusses the recently FDA approved drug ixazomib (Ninlaro®).

Bottom Line:

Ninlaro is an important addition to the lineup of myeloma treatments.

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
What should we know about FDA approval of daratumumab?
Next Post
The Black Swan Research Initiative Is the “Myeloma Moonshot”

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.